Načítá se...
Iodine‐131‐meta‐iodobenzylguanidine therapy for patients with newly diagnosed high‐risk neuroblastoma
BACKGROUND: Patients with newly diagnosed high‐risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi‐modality intensive therapy. This poor outcome necessitates the search for new therapies, such as treatment with (131)I‐meta‐iodobenzylguanidine ((131)I‐MIBG). OBJECTIVES: To assess t...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2017
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478145/ https://ncbi.nlm.nih.gov/pubmed/28429876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010349.pub2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|